fda compounding glp-1 crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our DTC Ad Crackdown: US FDA

Some evidence suggests that increasing NAD may lower the risk for obesity and metabolic syndrome and the conditions they can cause, including heart disease, type 2 diabetes, and stroke, but the science is mixed with some research showing no improvements related to insulin resistance

AOD-9604 exhibits strong lipolytic activity The primary task of AOD-9604 is to stimulate lipolysisthe process of breaking down and burning fatand to inhibit lipogenesisthe process of creating new fat cells

Wegovy Treatment Millions of Americans, including those in Kingston, New York, grapple with obesitya condition that significantly impacts both physical health and mental well-being

Endotoxins trigger immune reactions even when a compound looks visually clean

Your potential goes to waste

The increasingly nuanced molecular subtypes of breast cancer have enhanced the comprehension and precision treatment of this disease